Ammar Al‐Chalabi

58.3k citations

270 papers · 18.2k indexed · 8 hit papers · h-index 64

Impact in

Neurology top 0.01%
- Amyotrophic Lateral Sclerosis Research
- Parkinson's Disease Mechanisms and Treatments
- Neurological diseases and metabolism
Genetics top 0.02%
- Neurogenetic and Muscular Disorders Research

Papers in

Neurology 237
- Amyotrophic Lateral Sclerosis Research 231
- Parkinson's Disease Mechanisms and Treatments 66
- Neurological diseases and metabolism 42
Genetics 148
- Neurogenetic and Muscular Disorders Research 148

Co-authors: Orla Hardiman Robert H. Brown Christopher E. Shaw Peter M. Andersen P. Nigel Leigh Adriano Chiò Leonard H. van den Berg Martin R. Turner
Journals: Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration (54 papers)Journal of Neurology Neurosurgery & Psychiatry (24 papers)Neurology (14 papers)Brain (11 papers)Neurobiology of Aging (11 papers)
Partner nations: United Kingdom United States Italy

In The Last Decade

Ammar Al‐Chalabi

262 papers receiving 17.9k citations

Hit Papers

8 papers align trajectories log scale

European Academy of Neurology (EAN) guideline on the management of amyotrophic lateral sclerosis in collaboration with European Reference Network for Neuromuscular Diseases (ERNEURO‐NMD) 2024 · 43 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2024 European Journal of Neurology
2022 The Lancet Neurology
2017 New England Journal of Medicine
2017 Nature Reviews Disease Primers
2017 The Lancet
2013 Nature Reviews Neurology
2011 Nature Reviews Neurology
2008 Science

Peers

Countries citing papers authored by Ammar Al‐Chalabi

Since Specialization

Citations

This map shows the geographic impact of Ammar Al‐Chalabi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ammar Al‐Chalabi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ammar Al‐Chalabi more than expected).

Fields of papers citing papers by Ammar Al‐Chalabi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ammar Al‐Chalabi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ammar Al‐Chalabi. The network helps show where Ammar Al‐Chalabi may publish in the future.

Co-authors

The 25 scholars most cited alongside Ammar Al‐Chalabi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Ammar Al‐Chalabi Line = papers co-authored together Ammar Al‐Chalabi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Landscapes of missense variant impact for human superoxide dismutase 1 The American Journal of Human Genetics ·Anna Axakova, M. Ding, Atina G. Coté, Radha Subramaniam, Vignesh Senguttuvan, Haotian Zhang, Jochen Weile, Samuel V. Douville, Marinella Gebbia, Ammar Al‐Chalabi, Alexander Wahl, Jason Reuter, Jessica A. Hurt, Adele A. Mitchell, Stephanie Fradette, Peter M. Andersen, Warren van Loggerenberg, Frederick P. Roth	2025	0
2	The reliability and validity of in-person and remote behavioural screening tools for people with amyotrophic lateral sclerosis Journal of the Neurological Sciences ·Lyndsay Didcote, Silia Vitoratou, Ammar Al‐Chalabi, Laura H. Goldstein	2024	1
3	Harnessing transcriptomic signals for amyotrophic lateral sclerosis to identify novel drugs and enhance risk prediction Heliyon ·Oliver Pain, Ashley Jones, Ahmad Al Khleifat, Devika Agarwal, Dzmitry Hramyka, Hajer Karoui, Jędrzej Kubica, David J. Llewellyn, Janice M. Ranson, Zhi Yao, Alfredo Iacoangeli, Ammar Al‐Chalabi	2024	4
4	SOD1-ALS-Browser: a web-utility for investigating the clinical phenotype in SOD1 amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Thomas P Spargo, Sarah Opie-Martin, Guy P Hunt, Munishikha Kalia, Ahmad Al Khleifat, Simon Topp, Christopher E. Shaw, Ammar Al‐Chalabi, Alfredo Iacoangeli, (unknown)	2023	3
5	UNC13Ain amyotrophic lateral sclerosis: from genetic association to therapeutic target Journal of Neurology Neurosurgery & Psychiatry ·Sean W. Willemse, Peter Harley, Ruben P. A. van Eijk, Koen C. Demaegd, Pavol Zelina, R. Jeroen Pasterkamp, Philip Van Damme, Caroline Ingre, Wouter van Rheenen, Jan H. Veldink, Matthew C. Kiernan, Ammar Al‐Chalabi, Leonard H. van den Berg, Pietro Fratta, Michael A. van Es	2023	25
6	Integrated transcriptome landscape of ALS identifies genome instability linked to TDP-43 pathology Nature Communications ·Oliver J. Ziff, Jacob Neeves, Jamie S. Mitchell, Giulia E. Tyzack, Carlos Martínez‐Ruiz, Raphaëlle Luisier, Anob M. Chakrabarti, Nicholas McGranahan, Kevin Litchfield, Simon J. Boulton, Ammar Al‐Chalabi, Gavin Kelly, Jack Humphrey, Rickie Patani	2023	36
7	Molecular dynamics analysis of superoxide dismutase 1 mutations suggests decoupling between mechanisms underlying ALS onset and progression Computational and Structural Biotechnology Journal ·Munishikha Kalia, Mattia Miotto, Deborah Ness, Sarah Opie-Martin, Thomas P Spargo, Lorenzo Di Rienzo, Tommaso Biagini, Francesco Petrizzelli, Ahmad Al Khleifat, Renata Kabiljo, Tommaso Mazza, Giancarlo Ruocco, Edoardo Milanetti, Richard Dobson, Ammar Al‐Chalabi, Alfredo Iacoangeli	2023	12
8	C9orf72 Repeat Expansion Discordance in 6 Multigenerational Kindreds Neurology Genetics ·Marie Ryan, Mark A. Doherty, Ahmad Al Khleifat, Emmet Costello, Jennifer C. Hengeveld, Mark Heverin, Ammar Al‐Chalabi, Russell L. McLaughlin, Orla Hardiman	2023	3
9	Comparison Of King’s Clinical Staging In Multinational Amyotrophic Lateral Sclerosis Cohorts Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Rubika Balendra, Ashley Jones, Ahmad Al Khleifat, Theresa Chiwera, Paul Wicks, Carolyn Young, Pamela J. Shaw, Martin R. Turner, P. Nigel Leigh, Ammar Al‐Chalabi	2022	2
10	The importance of offering early genetic testing in everyone with amyotrophic lateral sclerosis Brain ·Kristiana Salmon, Matthew C. Kiernan, Seung Hyun Kim, Peter M. Andersen, Adriano Chiò, Leonard H. van den Berg, Philip Van Damme, Ammar Al‐Chalabi, Patricia Lillo, Jinsy Andrews, Angela Genge	2021	24
11	The use of biotelemetry to explore disease progression markers in amyotrophic lateral sclerosis Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Madeline L Kelly, Arseniy Lavrov, Luis Garcia‐Gancedo, Jim Parr, Robert G. Hart, Theresa Chiwera, Christopher E. Shaw, Ammar Al‐Chalabi, Rachael Marsden, Martin R. Turner, Kevin Talbot	2020	17
12	Evolution of white matter damage in amyotrophic lateral sclerosis Annals of Clinical and Translational Neurology ·Matt C. Gabel, Rebecca Broad, Alexandra L. Young, Sharon Abrahams, Mark E. Bastin, Ricarda Menke, Ammar Al‐Chalabi, Laura H. Goldstein, Stella Tsermentseli, Daniel C. Alexander, Martin R. Turner, P. Nigel Leigh, Mara Cercignani	2020	16
13	Improving clinical trial outcomes in amyotrophic lateral sclerosis Nature Reviews Neurology ·Matthew C. Kiernan, Steve Vucic, Kevin Talbot, Christopher McDermott, Orla Hardiman, Jeremy M. Shefner, Ammar Al‐Chalabi, William Huynh, Merit Cudkowicz, Paul Talman, Leonard H. van den Berg, Thanuja Dharmadasa, Paul Wicks, C.M. Reilly, Martin R. Turner	2020	178
14	Objectively Monitoring Amyotrophic Lateral Sclerosis Patient Symptoms During Clinical Trials With Sensors: Observational Study JMIR mhealth and uhealth ·Luis Garcia‐Gancedo, Madeline L Kelly, Arseniy Lavrov, Jim Parr, R G Hart, Rachael Marsden, Martin R. Turner, Kevin Talbot, Theresa Chiwera, Christopher E. Shaw, Ammar Al‐Chalabi	2019	41
15	Striking phenotypic variation in a family with the P506S UBQLN2 mutation including amyotrophic lateral sclerosis, spastic paraplegia, and frontotemporal dementia Neurobiology of Aging ·Soragia Athina Gkazi, Claire Troakes, Simon Topp, Jack W. Miller, Caroline Vance, Jemeen Sreedharan, Ammar Al‐Chalabi, Janine Kirby, Pamela J. Shaw, Safa Al‐Sarraj, Andrew King, Bradley Smith, Christopher E. Shaw	2018	15
16	Measuring reliable change in cognition using the Edinburgh Cognitive and Behavioural ALS Screen (ECAS) Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Christopher Crockford, Judith Newton, Katie Lonergan, Caoifa Madden, Iain Mays, Meabhdh O’Sullivan, Emmet Costello, Marta Pinto‐Grau, Alice Vajda, Mark Heverin, Niall Pender, Ammar Al‐Chalabi, Orla Hardiman, Sharon Abrahams	2017	30
17	ECAS A-B-C: alternate forms of the Edinburgh Cognitive and Behavioural ALS Screen Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Christopher Crockford, Michaela Kleynhans, Evelyn Wilton, Ratko Radaković, Judith Newton, Elaine Niven, Ammar Al‐Chalabi, Orla Hardiman, Thomas H. Bak, Sharon Abrahams	2017	21
18	Psychological as well as illness factors influence acceptance of non-invasive ventilation (NIV) and gastrostomy in amyotrophic lateral sclerosis (ALS): A prospective population study Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration ·Naomi Martin, Sabine Landau, Anna Janssen, Rebecca Lyall, Irene J Higginson, Rachel Burman, Paul McCrone, Mohammed Sakel, C. M. Ellis, Christopher E. Shaw, Ammar Al‐Chalabi, P. Nigel Leigh, Laura H. Goldstein	2014	44
19	TDP-43 Mutations in Familial and Sporadic Amyotrophic Lateral Sclerosis Science ·Jemeen Sreedharan, Ian P. Blair, Vineeta B. Tripathi, Xun Hu, Caroline Vance, Boris Rogelj, Steven Ackerley, Jennifer C. Durnall, Kelly L. Williams, Emanuele Buratti, Francisco E. Baralle, Jacqueline de Belleroche, John D. Mitchell, P. Nigel Leigh, Ammar Al‐Chalabi, Christopher C.J. Miller, Garth A. Nicholson, Christopher E. Shaw Hit paper breakdown →	2008	2037
20	Recent advances in amyotrophic lateral sclerosis Current Opinion in Neurology ·Ammar Al‐Chalabi, P. Nigel Leigh	2000	105

About Ammar Al‐Chalabi

Ammar Al‐Chalabi is a scholar working on Neurology, Genetics, Neurology, Cellular and Molecular Neuroscience and Molecular Biology, having authored 270 papers that have together received 18.2k indexed citations. Recurring topics across this work include Amyotrophic Lateral Sclerosis Research (231 papers), Neurogenetic and Muscular Disorders Research (148 papers), Parkinson's Disease Mechanisms and Treatments (66 papers), Neurological diseases and metabolism (42 papers), Prion Diseases and Protein Misfolding (30 papers), Alzheimer's disease research and treatments (18 papers), Genetic Neurodegenerative Diseases (12 papers) and Cholinesterase and Neurodegenerative Diseases (9 papers). The work is most often cited by research in Neurology (14.8k citations), Genetics (8.2k citations), Neurology (3.3k citations), Cellular and Molecular Neuroscience (2.1k citations) and Physiology (2.6k citations). Ammar Al‐Chalabi has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Orla Hardiman, Robert H. Brown, Christopher E. Shaw, Peter M. Andersen, P. Nigel Leigh, Adriano Chiò, Leonard H. van den Berg, Martin R. Turner, P. Nigel Leigh and Jan H. Veldink. Their work appears in journals such as Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, Journal of Neurology Neurosurgery & Psychiatry, Neurology, Brain and Neurobiology of Aging.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact